{"preliminary_commentary":{"by_channel":{"bluesky_thread":4,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"TAR-210","nct_id":"NCT05567185","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tar-210-nct05567185. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TAR-210","arms":[{"description":"Participants with bladder cancer and fibroblast growth factor receptor (FGFR) mutations or fusions will receive erdafitinib intravesical delivery system and study will evaluate 2 dose levels of erdafitinib. Participants with a complete response (CR) may continue to receive treatment up to a duration of 1 year as long as there is no disease recurrence or progression, intolerable toxicity or withdrawal of consent.","label":"Dose Escalation: Erdafinitib Intravesical Delivery System","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-08-30","type":"ESTIMATED"},"conditions":["Urinary Bladder Neoplasms","Receptors, Fibroblast Growth Factor"],"enrollment":{"count":5,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Erdafitinib Intravesical Delivery System","otherNames":["JNJ-42756493"],"type":"DRUG"}],"last_update":"2026-08-28","lead_sponsor":"Janssen Pharmaceutical K.K.","official_title":"A Phase 1 Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of TAR-210 in Japanese Participants With Bladder Cancer and Selected FGFR Mutations or Fusions","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2025-03-11","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants with Dose-limiting Toxicity (DLT)","timeFrame":"Up to 28 days"}],"references":[],"start_date":{"date":"2023-03-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT05567185"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tar-210-nct05567185"}